Name: Nova Eye Medical (EYE) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

EYE

Nova Eye Medical

Health Care Equipment & Services

Nova Eye Medical is a medical device company focused on developing and commercializing innovative technologies for the treatment of glaucoma. Their proprietary technologies, including the iTrack™ family of canaloplasty devices and the Molteno3® glaucoma drainage device, offer comprehensive treatment options for ophthalmologists. The company collaborates with surgeons and researchers to develop solutions that address unmet needs in glaucoma management.

Short position

short percentage0.01%

reported shorts29.9K

shares on issue284.921M

Nova Eye Medical (ASX:EYE) has 0.01% of its shares on issue reported as short positions as of 29 Sept 2026, or about 29,862 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.17% in January 2025. EYE is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Weekly context: The 10 most shorted ASX stocks — Week 40, 2026.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

EYE intelligence dossier

Public-source evidence for this company, with industry drill-up links.

Tax paid and taxable income records
Government contracts and public money
Emissions and trade exposure
Political donations and lobbying links

Short interest history & FAQ

EYE Short Interest History

30-day change: -0.00pp
90-day change: -0.00pp
1-year change: +0.00pp
All-time high: 0.17% (January 2025)
All-time low: 0.01% (July 2020)

Is EYE heavily shorted?

Not especially: 0.01% short interest is modest by ASX standards, ranking #592 of 810 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.

How has EYE's short interest changed recently?

Over the past 30 days Nova Eye Medical's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.01% of shares on issue.

What is the highest EYE's short interest has been?

Since 2020, Nova Eye Medical's short interest peaked at 0.17% in January 2025 and bottomed at 0.01% in July 2020.

Where does this data come from?

All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2020. See our methodology.

EYE fundamentals

In the year to 30 Jun 2026, Nova Eye Medical (ASX:EYE) recorded revenue of A$34.9M and a net loss after tax of A$4.3M. A year earlier it recorded revenue of A$29.3M and a net loss after tax of A$9.1M. Year-on-year growth: revenue +19.1% (FY). Net margin −12.4% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 29 Sep 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Strategy fit

How each stock picker strategy reads EYE today

PassFailUnknown (data missing, or not meaningful for this company)

Zanger Breakout
WatchScore 22rank 1125 of 1966
- 1. Explosive growth: fail. Revenue +19.1% YoY (FY ending 2026-06-30); still loss-making on EPS (FY ending 2026-06-30); below the +25% threshold
- 2. A recognisable base: pass. 39-session base, 21.2% deep; close A$0.13 holds above the base low A$0.13
- 3. Breakout on heavy volume: fail. No close above the A$0.17 pivot on 1.5x volume in the last 5 sessions; close is -21.2% from the pivot
- 4. Read the market first: fail. XJO in a downtrend: below its 200-day average
- 5. Relative strength: pass. Beat the S&P/ASX 200 by 18.7 points over 3 months
- 6. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
CAN SLIM
Not a candidate
- 1. Earnings growth (C and A): fail. Still loss-making on EPS (FY ending 2026-06-30)
- 2. Sales growth: fail. Revenue +19.1% YoY (FY ending 2026-06-30); below the +20% threshold
- 3. New highs (N): fail. 36.6% below the 52-week high, more than 5% away
- 4. Leader, not laggard (L): fail. 6-month relative strength +2.8 points, below the top-quartile cut-off of +6.9
- 5. Market direction (M): fail. XJO in a downtrend: below its 200-day average
- 6. Supply and demand (S): fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
Minervini Trend Template
WatchScore 15rank 1178 of 1782
- 1. Above rising averages: fail. Close A$0.13, 150-day A$0.13, 200-day A$0.14: 150-day is not above the 200-day
- 2. 200-day trending up: pass. 200-day average A$0.14 vs A$0.14 a month ago (+0.0%)
- 3. Well off the low: pass. Close A$0.13 is 30.0% above the 52-week low of A$0.10
- 4. Near the high: fail. 36.6% below the 52-week high, more than 25% away
- 5. Relative strength: fail. 6-month relative strength +2.8 points, below the top-quartile cut-off of +6.9
- 6. Above the 50-day: fail. Close A$0.13 vs 50-day average A$0.14 (-5.7%)
- 7. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
Crowded-Short Breakout
WatchScore 13rank 794 of 1555
- 1. Crowded short: fail. 0.01% of shares on issue reported short, under 5%
- 2. Days to cover: fail. 0.2 days of average volume to cover, under 5
- 3. Breakout on heavy volume: fail. No close above the A$0.17 pivot on 1.5x volume in the last 5 sessions; close is -21.2% from the pivot
- 4. Market direction: fail. XJO in a downtrend: below its 200-day average
- 5. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
- 6. Relative strength: pass. Beat the S&P/ASX 200 by 18.7 points over 3 months
Quality compounders
WatchScore 10rank 1358 of 1687
- 1. High return on equity: unknown. Return on equity cannot be measured: it needs net profit, equity at both ends of the year and, outside banks, insurers and other financials, equity of at least 10% of total assets
- 2. Healthy profit margin: fail. Net margin -12.4% (FY ending 2026-06-30), below the 10% threshold
- 3. Profit that turns into cash: fail. Net profit is zero or negative, so there is no profit to convert to cash (FY ending 2026-06-30)
- 4. Little debt: unknown. Net debt cannot be measured: no aligned balance sheet with debt and cash
- 5. Liquid enough to trade: fail. A$20k average daily turnover over 20 sessions, below the A$250k floor
- 6. Long-term uptrend: fail. Close A$0.13 vs 200-day average A$0.14 (-4.3%): not above the 200-day average
- 7. Revenue not shrinking: pass. Revenue +19.1% YoY (FY ending 2026-06-30)